AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) has hired an American investor relations firm as it seeks to woo US investors, ahead of the next wave of progress at the AIM-quoted firm's Alaskan oil and gas assets. It has appointed MZ Group to lead its investor relations efforts in the US.
The potential removal of inheritance tax relief on AIM-listed shares in the upcoming UK Budget has sparked concerns among investors, with many viewing the change as "painful" and "unnecessary". However, Marcus Stuttard, head of AIM and UK primary markets at the London Stock Exchange, doesn't expect Chancellor Rachel Reeve's impending tax raid to be a death knell for the junior market.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, PORTUGAL / ACCESSWIRE / October 18, 2024 / Pulsar Helium Inc. (AIM:PLSR)(TSXV:PLSR)(OTCQB:PSRHF) ("Pulsar" or the "Company"), the helium project development company, is pleased to announce that its common shares will commence trading today, 18 October 2024, on the AIM market of the London Stock Exchange plc ("AIM") (the "Admission").
Pulsar Helium Inc (TSXV:PLSR, OTC:PSRHF), an explorer focused on acreage in Minnesota, has confirmed the completion of a £3.88 million (C$7 million) equity raise, ahead of joining the AIM market later this week. Including a prior pre-IPO raise of £1.13 million, Pulsar will come to the London market holding around £5 million of cash.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, PORTUGAL / ACCESSWIRE / October 15, 2024 / Pulsar Helium Inc. (AIM:PLSR)(TSXV:PLSR)(OTCQB:PSRHF) ("Pulsar" or the "Company"), the helium project development company, is pleased to announce that it has conditionally raised £3.875 million (C$7 million) (before expenses), through a placing of new common shares with new and existing investors (the "Fundraising") and is today publishing an AIM admission document ("Admission Document") in connection with the admission of the enlarged share capital of the Company to trading on the AIM Market of the London Stock Exchange plc ("AIM")("Admission").
Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) chief executive Andrew Benitz, in today's interim results statement, highlighted February's farm-out to Serica Energy as testament to the quality of the GBA asset, a project the AIM-quoted firm nurtured from inception. It added to prior deal with NEO Energy, and, ensured Jersey was fully funded for its remaining 20% interest in the Buchan development project.
Occupational health specialist Optima Health PLC will begin life as a stand-alone company on the AIM section of the London Stock Exchange later this month after being spun out of Marlow PLC. The Glasgow-based firm said it has no intention to raise new capital in connection with admission.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. This announcement is an advertisement and not an admission document or a prospectus and does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever in any jurisdiction.
AIM ImmunoTech Inc. (NYSE:AIM ) Q2 2024 Earnings Conference Call August 16, 2024 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President & Executive Vice Chairman Christopher McAleer - Scientific Officer Conference Call Participants Operator Hello, and welcome to the AIM ImmunoTech Second Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Why is AIM so terrible at recognising potential, let alone putting a realistic value on it – even as it is crystallising? A case in point: Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) (up 7% this week).
Hermes Pacific Investment's shares sank 23% on news of the property-focused investment company's planned delisting from AIM. Hermes Pacific has struggled to find attractive opportunities in the recent period of escalating interest rates, with no new investments made in the past two years.